Status | Study |
Completed |
Study Name: Allogenic Bone Marrow Derived Mesenchymal Stem Cell Therapy in Cases of Hemophilia Condition: Hemophilia Date: 2014-02-15 Interventions: Biological: Cellular therapy b |
Recruiting |
Study Name: Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A Condition: Haemophilia A Date: 2013-03-13 Interventions: Biological: Optivate 500IU |
Completed |
Study Name: Quality of Life in Adult Patients With Severe Haemophilia in Turkey Condition: Haemophilia Date: 2012-06-17 |
Completed |
Study Name: Inhibitor Development in Patients With Hemophilia A Undergoing Surgery Condition: Hemophilia A Date: 2012-04-04 |
Active, not recruiting |
Study Name: A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A Condition: Hemophilia A Date: 2012-03-28 Interventions: Biological: BAY94-9027 Intravenous infusion of BAY94-9027 |
Completed |
Study Name: Turkish Acquired Haemophilia Registry Condition: Acquired Haemophilia Date: 2011-07-26 Interventions: Drug: rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin According to local clinical stan |
Completed |
Study Name: Study of Biostate® in Children With Hemophilia A Condition: Hemophilia A Date: 2010-10-01 Interventions: Biological: Biostate 1 dose of 50 IU FVIII/kg body weight of Biostate administered intravenously on Day |
Completed |
Study Name: Canadian Hemophilia Prophylaxis Study Condition: Severe Hemophilia A Date: 2010-03-01 Interventions: Biological: Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS) |
Completed |
Study Name: Bleeding Symptoms of Carriers of Hemophilia A and B Condition: Hemophilia Date: 2009-12-09 |
Completed |
Study Name: Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients Condition: Hemophilia A Date: 2009-06-04 Interventions: Biological: Moroctocog alfa ( AF-CC) |